Cara Therapeutics, Inc. (CARA)

Market Cap	90.85M
Revenue (ttm)	27.17M
Net Income (ttm)	-111.66M
Shares Out	54.08M
EPS (ttm)	-2.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	419,306
Open	1.69
Previous Close	1.69
Day's Range	1.67 - 1.74
52-Week Range	1.59 - 12.81
Beta	0.87
Analysts	Strong Buy
Price Target	17.50 (+941.67%)
Earnings Date	Nov 6, 2023

About CARA

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 106
• Stock Exchange: NASDAQ
• Ticker Symbol: CARA

Financial Performance

In 2022, CARA's revenue was $41.87 million, an increase of 81.81% compared to the previous year's $23.03 million. Losses were -$85.47 million, -3.35% less than in 2021.

Analyst Forecast

According to 8 analysts, the average rating for CARA stock is "Strong Buy." The 12-month stock price forecast is $17.5, which is an increase of 941.67% from the latest price.

Price Target

$17.5

(941.67% upside)

Analyst Consensus: Strong Buy